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Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a
significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibodies, like
trastuzumab or pertuzumab, and ATP active site inhibitors like lapatinib, commonly lack durability because of adaptive changes in
the tumor leading to resistance. HER2+ cell line responses to inhibition with lapatinib were analyzed by RNAseq and ChIPseq to
characterize transcriptional and epigenetic changes. Motif analysis of lapatinib-responsive genomic regions implicated the pioneer
transcription factor FOXA1 as a mediator of adaptive responses. Lapatinib in combination with FOXA1 depletion led to
dysregulation of enhancers, impaired adaptive upregulation of HER3, and decreased proliferation. HER2-directed therapy using
clinically relevant drugs (trastuzumab with or without lapatinib or pertuzumab) in a 7-day clinical trial designed to examine early
pharmacodynamic response to antibody-based anti-HER2 therapy showed reduced FOXA1 expression was coincident with
decreased HER2 and HER3 levels, decreased proliferation gene signatures, and increased immune gene signatures. This highlights
the importance of the immune response to anti-HER2 antibodies and suggests that inhibiting FOXA1-mediated adaptive responses
in combination with HER2 targeting is a potential therapeutic strategy.
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INTRODUCTION
Amplification and overexpression of v-erb-b2 erythroblastic
leukemia viral oncogene homolog 2 (ERBB2, also known as
HER2) occurs in up to 20% of breast cancers and defines a distinct
clinical and molecular subtype1–3. HER2 is a receptor tyrosine
kinase belonging to the epidermal growth factor receptor (EGFR)
family that also includes HER3 (ERBB3) and HER4 (ERBB4)4.
Consistent with the notion of oncogene addiction, treatment of
HER2+ breast cancer has been significantly impacted by HER2-
targeted therapies. Adding the anti-HER2 humanized monoclonal
antibody trastuzumab, which targets the extracellular domain, to
chemotherapy in early curable breast cancer decreases relapse
and death by nearly 40%5. The development of additional HER2-
targeted treatment options has expanded to include pertuzumab,
a monoclonal antibody that blocks HER2 dimerization and
significantly improves outcomes when added to trastuzumab-
based therapy. Additionally, trastuzumab–emtansine and
trastuzumab–deruxtecan, antibody–drug conjugates approved
for adjuvant therapy (trastuzumab–emtansine) or later-line meta-
static disease, and small-molecule tyrosine kinase inhibitors, such
as tucatinib, lapatinib, and neratinib, which target EGFR and HER26
are approved in the metastatic or adjuvant settings, usually with
or after trastuzumab. In metastatic or early disease, up to 50% of
patients respond to combinations of these HER2-targeting agents
given with chemotherapy, however response rates to anti-HER2
therapy alone are low, and resistance remains a challenge. In the
metastatic setting, continued HER2-targeting is standard across all
lines of therapy, however, this is generally in combination with
other drugs and virtually all ultimately experience disease
progression and death.
Genomic and transcriptomic studies of HER2+ breast cancer
have revealed substantial tumor and microenvironmental
heterogeneity. While all intrinsic subtypes are represented,
HER2+ breast cancer is primarily comprised of the HER2-
Enriched, Luminal A, and Luminal B subtypes. Intrinsic subtype
significantly impacts response to HER2-targeted therapy
(reviewed in ref. 7). Evidence of immune activation, either by
histologic presence of tumor infiltrating lymphocytes (TILS) or
by immune gene expression, also significantly impacts response
to HER2-directed therapy8–10.
In contrast to intrinsic resistance, characterized by initial failure
to respond to HER2-targeted therapy, HER2+ tumors that respond
to HER2-directed therapy often develop acquired resistance
resulting in disease progression. Resistance has been attributed
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to numerous mechanisms, including the expression of a truncated
HER2 (p95 HER2) that fails to bind trastuzumab, upregulation of
downstream signaling via the PI3K/AKT pathway, and upregula-
tion and increased signaling through alternate kinase pathways.
The emergence of acquired resistance is due to the adaptive
tumor responses to HER2 inhibition11–13. The adaptive response to
targeted kinase inhibition involves disruptions in feedback and
feedforward signaling loops that lead to dramatic epigenetic and
transcriptional changes within the tumor cells themselves, as well
as stromal and immune cell populations13,14. A major contributor
to anti-HER2 treatment in HER2+ disease is the resultant
upregulation of HER3, the preferred heterodimerization partner
of HER24,15. HER2/HER3 heterodimers drive oncogenic signaling,
predominantly via the PI3K/AKT pathway and the upregulation of
HER3 and other kinases has been shown to overcome HER2
inhibition11,12,16–18.
Adaptive responses to kinase inhibition have been observed in
cell lines, animal models, and patient populations at early time
points following treatment14,19. Adaptive kinome responses to
MEK1/2 inhibition observed in triple-negative breast cancer
patients after 7 days was shown in preclinical models to be
dependent on transcriptional changes resulting from epigenetic
genome-wide remodeling of the enhancer landscape20. The
transcriptional output of adaptive response genes is governed
by promoter and enhancer elements, including a number of
super-enhancers (SEs), which are clusters of enhancers that impart
cell identity21. A small number of master transcription factors (TFs)
bind to SEs and define a given cell type or lineage. It has been
hypothesized that these transcriptional regulatory programs may
constitute cancer cell dependencies that could be targeted
therapeutically22.
Studies from our laboratory have shown that the tumor cell-
intrinsic adaptive response to lapatinib in HER2+ models
resulted in the upregulation of HER3 and additional kinases,
each contributing to resistance. The combination of lapatinib
with the bromodomain and extra-terminal domain (BET)
inhibitor, JQ1, was capable of blocking the transcription of
kinases involved in the adaptive response and was more
durable than lapatinib alone in growth suppression12. The BET
family member BRD4 is an epigenetic reader, recognizing
acetylated lysine residues on histones or other proteins and
binding to key gene promoters and enhancers21,23,24. Here, we
extend our findings by determining the global alterations in
gene enhancers and transcriptional changes to identify factors
involved in the adaptive response to HER2 inhibition. In parallel,
we analyzed the in vivo human adaptive molecular responses to
HER2 targeting in a window-of-opportunity clinical trial using
both RNAseq and a chemical proteomics method (MIB/MS) to
assess the functional kinome.
Integrative analysis of adaptive response SEs and mRNA
expression identified a shared motif bound by FOXA1, a pioneer
factor for estrogen receptor (ER). We show that FOXA1 is
essential for the proliferation of HER2+/ER− cells and for the
lapatinib-dependent upregulation of numerous genes, includ-
ing HER3. In a window-of-opportunity trial using FDA-approved
HER2-targeting drugs, a subset of patients exhibited a striking
molecular response after 7 days of therapy. The expression of
FOXA1 was drastically reduced in this subset, coincident with
decreased HER2 and HER3 expression, decreased proliferation
pathway signatures, and increased immune signatures. The
strongest molecular responsive samples had higher HER2
amplicon pathway scores at baseline. Our studies implicate
FOXA1 as a mediator of dynamic and adaptive transcriptional
responses to HER2-targeted therapy.
RESULTS
Epigenetic dysregulation induced by concurrent inhibition of
HER2 and BET bromodomains
Our prior studies demonstrated the adaptive response and
acquired resistance patterns of the kinome to lapatinib treatment
could be blocked by JQ112. ChIP-PCR revealed that JQ1 alone
could disrupt BRD4 association with the HER2 and HER3 gene
promoters. Global analysis using ChIPseq revealed broad epige-
netic alterations induced by HER2 targeting (Fig. 1a). BRD4 is a
critical mediator of cell identity controlling enhancer architecture
in response to perturbations such as kinase inhibitors. Although
the strict classification of SEs can vary, a unifying feature of SEs is
the heightened enrichment of BRD4, mediator subunit MED1,
binding of master transcription factors, and acetylation of lysine
27 of histone H3 (H3K27ac)22,25. Given our interest in identifying
the kinases potentially impacted by the BET bromodomain
inhibitor JQ1, we focused on the regions with highest BRD4
ChIPseq density. Analysis of BRD4 density by ChIPseq was used to
identify SEs and their classification based on their location in the
genome (enhancer, promoter, gene body intron, gene body exon,
3 prime, or other, see “Methods”) in an unbiased fashion in two
HER2+ breast cancer cell lines, SKBR-3 (ER−/PR−) and BT474.m1
(ER+/PR+) (Fig. 1b, Supplementary Fig. 1a and Supplementary
Data 1 and 2). Ranking BRD4 enrichment by ChIPseq density can
be used to classify SEs regulating genes critical for cell identity21.
The majority of identified BRD4 peaks (74%) were classified as
promoter or enhancer regions based on genomic location and
virtually all of the identified SEs (95%) in SKBR-3 cells were
classified as promoter or enhancer regions. BRD4 was highly
enriched proximal to HER2 and the essential proto-oncogene MYC.
Other BRD4-enriched regions identified were proximal to TFs,
including ELF3, ZNF217, FOXA1, and PBX1, each with recognized
function in epithelial cell identity and in breast cancer26–29. BRD4
enrichment at the estrogen receptor alpha gene, ESR1, was
identified only in the HER2+/ER+ BT474.m1 cells (Supplementary
Fig. 1a). Shared BRD4 enrichment and SE classification between
the two cell lines was observed at HER2, FOXA1, and PBX1 (Fig. 1b
and Supplementary Fig. 1a). FOXA1 and PBX1 have been
characterized as pioneer factors for ER, important for increasing
chromatin accessibility for ER and other TFs28,29. As expected, the
enrichment of BRD4 near the HER2 locus coincided with mediator
subunit MED1 chromatin association and the presence of the
active enhancer mark, H3K27Ac (Fig. 1c).
We previously demonstrated that JQ1 could prevent the
upregulation of numerous kinases contributing to lapatinib
response and resistance12. Analysis of enrichment in SKBR-3 and
BT474.m1 cells revealed that BRD4 and MED1 chromatin associa-
tion was significantly disrupted by the combination of lapatinib
and JQ1 at 24 h following treatment when compared to DMSO
(Fig. 1d and Supplementary Fig. 1b). Unsupervised hierarchical
clustering of BRD4 and MED1 relative ChIPseq density at all
genomic loci confirmed that the combination of lapatinib and JQ1
drastically disrupted their chromatin association (Fig. 1e). The
effects on ChIPseq density of BRD4 and MED1, were not due to a
reduction in total BRD4 protein levels as determined by
immunoblotting (Fig. 1f). The potent effect on BRD4 and MED1
chromatin association was consistent with 24 h exposure to
targeting BET proteins with JQ1.
Given the effectiveness of JQ1 in blocking the adaptive
response to lapatinib, we examined the impact of JQ1 on BRD4
and MED1 chromatin binding at regions most affected by
lapatinib alone (Fig. 1g and h, dot sizes proportional to ChIPseq
density). The top 500 regions with the highest BRD4 enrichment in
response to lapatinib were predominantly classified as promoter
or enhancer regions (95%, Supplementary Fig. 1e). The log2 fold
change for lapatinib versus DMSO is plotted on the x-axis and
identified regions that exhibited relative increased and decreased
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Fig. 1 Combined inhibition of HER2 and BET bromodomains induces broad epigenetic dysregulation. a Experimental strategy to identify
epigenetic and transcriptional adaptive responses to HER2 inhibition in cell line models using 300 nM lapatinib and 300 nM JQ1 for 24 h, alone
or in combination. b ChIPseq analysis of the HER2+ breast cancer cell line, SKBR-3, was performed to identify BRD4 binding sites. Super-
enhancers (456 regions) were identified as regions above the inflection point of increasing BRD4 ChIPseq density. c Multiple SEs identified by
high density of BRD4, MED1, and H3K27Ac are found flanking the HER2 locus. d BRD4 and MED1 binding to SE domains is significantly
reduced by the combination of lapatinib and JQ1, but H3K27Ac is unaffected. Box plots: median, upper/lower quartile, and 5–95 percentile.
Unpaired t-test, ***= P < 0.0001. e Unsupervised hierarchical clustering of all genomic loci bound by BRD4 and MED1. Lapatinib and JQ1 each
increase BRD4 and MED1 binding to discrete regions but the combination of drugs results in a loss of binding at the majority of loci. f Total
protein levels of BRD4 are largely unaffected by lapatinib and JQ1 as determined by immunoblotting of treated SKBR-3 cells. ERK2 was used as
a loading control. g, h The combination of lapatinib and JQ1 cooperatively reduce BRD4 and MED1 binding to HER2 and MYC. The top 500
regions of highest ChIPseq density in response to lapatinib are shown for g BRD4 and h MED1. The log2 fold change in density in response to
lapatinib vs. DMSO is plotted on the x-axis. The log2 fold change of lapatatinib+ JQ1 vs. lapatinib alone is plotted on the y-axis. Dot size is
relative to ChIP density in lapatinib.
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densities at the indicated loci. Strikingly, the comparison of
lapatinib combined with JQ1 to lapatinib alone (plotted on the
y-axis) revealed a dramatic effect on BRD4 and MED1 binding,
notably at regions proximal to HER2 and MYC. Similar findings
were observed in the HER2+/ER+ line, BT474.m1—specifically at
loci near HER2, ESR1 (estrogen receptor 1), and PGR (progesterone
receptor) (Supplementary Fig. 1c). Collectively, these data
indicated that lapatinib and JQ1 cooperatively disrupt BRD4 and
MED1 chromatin binding at a majority of genomic loci, consistent
with their capacity to elicit potent effects on adaptive responses
and suppress tumor cell growth12.
Regions with increased ChIPseq density and proximal mRNA
expression in response to lapatinib are enriched for a FOXA1-
binding motif
While the combination of lapatinib and JQ1 resulted in major
dysregulation of enhancers, we sought to better understand the
epigenetic changes occurring in response to lapatinib alone. We
identified SEs formed in response to lapatinib in SKBR-3 and
BT474.m1 cells (Fig. 2a and Supplementary Fig. 2a). Approximately
30 SEs were formed in SKBR-3 cells based on BRD4 association
following 24 h treatment with lapatinib. BRD4 and MED1 ChIPseq
density at these regions was suppressed by the addition of JQ1.
H3K27Ac at these lapatinib-induced regions was not affected by
the addition of JQ1 at 24 h following treatment. Overall, the global
changes in BRD4 in response to lapatinib correlated with H3K27Ac
and MED1 ChIPseq density (Fig. 2b and c).
While we had previously identified a heterogenous kinome
reprogramming response to lapatinib, we did not observe de novo
SE formation at these kinase genes (Supplementary Fig. 2b and c).
For example, SKBR-3 cells undergo increased expression of HER3
and DDR1 in response to lapatinib, but the ChIPseq density of
BRD4, MED1, and H3K27Ac did not increase at these genes
(Supplementary Fig. 2b and c). We confirmed increased SE
markers for some genes in response to lapatinib, such as PGR in
the ER+ BT474.m1 cell line (Supplementary Fig. 2d).
Since the SEs formed in response to lapatinib did not provide a
clear explanation for the adaptive kinome response, we employed
integrative analysis of the ChIPseq data with mRNA expression
data to identify underlying adaptive response factors. Lapatinib-
induced changes (log2 fold change) in ChIPseq density for BRD4,
MED1, and H3K27Ac (not only the regions designated as SEs) and
mRNA expression changes from RNAseq were utilized for
unsupervised hierarchical clustering, revealing that small subsets
of genes appeared to respond in similar fashion (Fig. 2d). In order
to define functional genomic elements, we identified underlying
genetic sequences that exhibited at least two-fold increases in
ChIPseq density and mRNA expression of proximal genes in
response to lapatinib. Dreme-TOMTOM analysis of these
sequences identified a single motif, GT(A/C)AACA, associated with
the FOX TFs, FOXA1, and FOXO3 (Fig. 2d). Analysis of the
normalized RNAseq read counts for the FOX family of TFs in SKBR-
3 cells indicated that FOXA1 is the most highly expressed
member. Using Enrichr to query the list of genes having shared
induction of local ChIPseq density and mRNA expression, we
identified a FOXA1 ChIPseq data set from HepG2 cells with the
highest combined score from the ENCODE ChIPseq 2015 data (Fig.
2e). Taken together, our analysis strongly suggested that FOXA1
was orchestrating the lapatinib-induced adaptive response.
We performed ChIPseq analysis of FOXA1 in the ER- SKBR-3 cell
line (Fig. 2f and Supplementary Data 1). The highest FOXA1
enrichment mapped to discrete gene regulatory regions including
the HER2 promoter and enhancer as well as enhancers for MYC.
Unsupervised hierarchical clustering of FOXA1 ChIPseq density
revealed the near global effect on FOXA1 chromatin association in
response to combined lapatinib and JQ1 treatment (Fig. 2g).
Lapatinib treatment combined with FOXA1 depletion by RNAi
strongly reduced the association of BRD4 with HER2 and MYC
enhancers when compared to lapatinib and a non-targeting
control siRNA (Fig. 2h and Supplementary Data 3). HER2 targeting
combined with JQ1 significantly reduced FOXA1 chromatin
binding genome-wide and similarly, targeting HER2 and FOXA1
disrupted enhancers at essential genes.
To determine whether FOXA1 was required for adaptive
transcriptional responses to HER2 targeting, gene expression in
response to lapatinib was analyzed by RNAseq with non-targeting
control or FOXA1 siRNA (Fig. 3a and Supplementary Data 4). The
log2 fold changes for kinases (blue) and TFs (orange) are shown
with the dot size proportional to the gene expression level in the
presence of lapatinib. FOXA1 depletion most notably reduced
the lapatinib-dependent induction of HER2, HER3, PBX1, and XBP1
(Fig. 3a). The expression of FOXA1 is also induced by lapatinib,
but the effects of siRNA targeting were more readily observed.
Closer inspection of the HER3 locus identified two intronic
enhancers displaying enhanced recruitment of FOXA1 following
lapatinib treatment (Supplementary Fig. 3). These regions are
blocked by JQ1 treatment and the intron 1 enhancer has been
previously implicated in HER3 regulation by specific TFs30–33. By
immunoblotting, we confirmed the depletion of FOXA1 and the
lapatinib-dependent induction of HER3 and compared the effects
of FOXO1 and FOXO3 depletion by RNAi, singly or in combination.
We did observe a lapatinib-induced increase in FOXO3 protein
levels. After FOXO3 RNAi treatment and 24 h lapatinib exposure,
there was no observable effect on phospho-HER2, phospho-AKT,
or phospho-ERK levels compared to lapatinib and control RNAi
(Fig. 3b).
To directly assess the requirement of FOXA1 for proliferation
and response to HER2 targeting, we performed cell proliferation
assays in the SKBR-3 and BT474.m1 cell lines (Fig. 3c). While both
cell lines are strongly responsive to lapatinib (compare blue to
gray lines), the effect of targeting FOXA1 alone by siRNA was
comparable to 300 nM lapatinib treatment in SKBR-3 cells and
resulted in the loss of BT474.m1 cells. In the Cancer Dependency
Map (depmap.org), the top FOXA1 co-dependencies from the
CRISPR screen data (AVANA) by Pearson correlation are SPDEF
followed by ESR1 (estrogen receptor alpha) and TRPS1, under-
scoring the critical interplay of FOXA1 and ESR134. In comparison,
siRNA knockdown of MYC inhibited proliferation in both ER+
BT474.m12 and ER− SKBR-3 cells, but less dramatically than HER2
targeting with lapatinib. Since our survey of super-enhancers had
identified a TF binding motif that potentially involved FOXO1 or
FOXO3, each gene was targeted by siRNA and in combination (Fig.
3c). FOXO1 and FOXO3 depletion did not impact cell growth when
compared to FOXA1. These data confirmed that adaptive
transcriptional responses to HER2 targeting, cell proliferation,
and survival were dependent on FOXA1 expression.
Distinct FOXA1 transcriptional response in a subset of
patients receiving anti-HER2 therapy
As our preclinical studies had underscored the importance of
rapid adaptive responses to kinase inhibitors, we initiated a
multi-center window-of-opportunity trial to illuminate these
changes in HER2+ patients receiving standard-of-care treatment.
Newly diagnosed stage I–IV HER2+ patients were enrolled into
LCCC1214 (Clinical Trials Identifier #NCT01875666), randomized
into four treatment groups and a pre-treatment/baseline fresh
biopsy of the primary tumor was obtained. All treatment arms
received a standard-of-care HER2-targeting antibody at standard
clinical doses, singly or in combination: trastuzumab (T),
pertuzumab (P), the combination of T+ P, or T plus lapatinib
(L) (Fig. 4a). Following seven days of therapy, patients returned
for scheduled surgical procedure. At the time of surgery, post-
treatment samples were obtained for analysis of adaptive
molecular changes in response to HER2 targeting. Analysis
S.P. Angus et al.
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a Lapatinib-induced super-enhancers
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Fig. 2 Lapatinib-induced ChIPseq and RNAseq changes are associated with FOX family transcription factors. a Lapatinib induces 30 SEs, as
determined by BRD4 ChIPseq density. Lapatinib in combination with JQ1 suppresses BRD4 binding in all regions, MED1 in all but one region,
but does not affect H3K27Ac. Box plots: median, upper/lower quartile, and 1.5 IQR. b, c Lapatinib-mediated changes are strongly correlated
with changes in H3K27Ac and MED1. d The log2 fold change binding in response to lapatinib for regions as in (a) and the log2 fold change in
mRNA expression for the proximal genes as determined by RNAseq was used for unsupervised hierarchical clustering. Genes included based
on ChIPseq density displayed increased chromatin association within 200 kb of transcription start site. Genes with shared induction in all
instances (log2 fold change ≥1) were used as input for Dreme-TOMTOM analysis to identify enriched binding motifs. A single motif identified,
GT(A/C)AACA, recognized by FOXA1 and FOXO3. Normalized RNAseq reads are shown for the FOX family of transcription factors in SKBR-3
cells after 48 h treatment with DMSO or 300 nM lapatinib. e Genes from (d) were used to query Enrichr. ENCODE TF ChIPseq data identified
FOXA1 and p300 as potential factors. f ChIPseq analysis of FOXA1 binding in SKBR-3 cells with the regions of highest density annotated by
proximal gene. g Unsupervised hierarchical clustering of FOXA1 ChIPseq density in SKBR-3 cells treated with DMSO, 300 nM lapatinib, and
300 nM JQ1, alone or in combination, at all genomic loci. Lapatinib and JQ1 each result in regions of increased FOXA1 chromatin binding. The
combination of lapatinib and JQ1 results in broad disruption of FOXA1. h SKBR-3 cells were treated with siRNA pools, nontargeting (NT)
control or FOXA1, prior to DMSO or 300 nM lapatinib treatment for 24 h and subsequent BRD4 ChIPseq analysis. The top 500 regions in
lapatinib are plotted. Log2 fold change of lapatinib vs. DMSO with a control siRNA pool are plotted on the x-axis. Log2 fold changes of
lapatinib vs. DMSO with FOXA1 knockdown are plotted on the y-axis. Dots are scaled relative to their lapatinib-induced ChIPseq density.
S.P. Angus et al.
5
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2021)    51 
included RNAseq to evaluate the transcriptional response to
therapy and a chemical proteomics assay (MIB/MS) to enrich and
quantify the functional kinome19,20,35.
For 13 patients, matched pre-treatment and post-treatment
samples were collected while for 8 additional patients, only a pre-
treatment or a post-treatment sample was obtained of sufficient
quality for analysis. DESeq2 analysis of transcriptome data from all
post-treatment samples versus all pre-treatment samples identi-
fied 185 genes that were significantly upregulated and associated
with immune signatures, including PD1 and PD-L1 individual gene
expression (Supplementary Fig. 4a, Supplementary Data 5, and
Supplementary Data 6). This is consistent with a role for innate
and adaptive immunity in response to HER2 antibody treatment36
and increasing recognition of the independent contribution of the
immune microenvironment to response to HER2-directed
drugs8,37. Other investigators have found that tumor infiltrating
lymphocytes or increased immune gene expression 7–15 days
after initiating trastuzumab or trastuzumab plus lapatinib are
associated with higher pathologic complete response after several
months of therapy38,39. Our data suggest specific immune
activation patterns are part of the earliest response pattern,
































































































































































































































































































































































Fig. 3 FOXA1 is critical for the HER2 targeting response and for proliferation in HER2+ cell lines. a RNAseq was performed on SKBR-3 cells
treated with DMSO or 300 nM lapatinib for 24 h after treatment with a non-targeting (NT) siRNA pool or FOXA1 siRNA pool. The log2 fold
changes in response to lapatinib are plotted as the NT siRNA effect (x-axis) versus FOXA1 siRNA effect (y-axis) for kinases (blue) and
transcription factors (orange). HER2 is indicated in red. Dots sizes are scaled relative to their expression level. b SKBR-3 cells were treated with
siRNA as in (a), then DMSO or 300 nM lapatinib for 24 h, harvested and subjected to immunoblotting to detect the indicated proteins. ERK2
was used as a loading control. c SKBR-3 and BT474.m1 cells were transfected with a NT siRNA pool or siRNA pools targeting the indicated
transcription factor (TF) and then treated with DMSO or 300 nM lapatinib for 8 days. Cell growth was quantified every two days and plotted as
the proportion of day 0 cell count. Data are plotted as mean ± s.d. for six replicates.
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similar across antibody-based anti-HER2 treatments. The log2 fold
change in expression for matched patient samples was used for
principal component analysis of the transcriptome (Fig. 4b). Three
matched pairs (from patients 116, 119, and 123) were notably
distant from the other 10 patient pairs.
We also observed segregation of these sample pairs by
unsupervised hierarchical clustering of the expressed kinome
(Supplementary Fig. 4b). The three distinct sample pairs repre-
sented three different treatment arms (patient 116, P; 119, T+ P,
123, T) so a specific treatment did not dictate their unique
transcriptional response. Within these HER2+ tumors based on
clinical criteria, all the molecular intrinsic subtypes were repre-
sented, however, there was no apparent relationship between
subtype and the kinome expression changes induced by HER2-
targeting drugs (Supplementary Fig. 4b).
Previous gene expression profiling studies have shown that
clinical HER2+ samples include HER2-Enriched, Luminal A, Luminal
B, Basal-like, and Normal-like subtypes and that the HER2-Enriched
subtype has markedly higher clinical and pathologic responsive-
ness to standard anti-HER2 drugs7,40. Most pre- and post-treatment
a bLCCC1214:
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matched pairs that were less molecularly dynamic retained the
same intrinsic subtype, with the exception of patient 125, whose
sample subtype changed from Luminal A to Luminal B, patient 108
(Luminal B to Luminal A), and 113 (Luminal A to Normal-like). In the
three strongly responsive paired samples, the intrinsic subtype of
patient 116 changed from Basal-like to HER2-Enriched, patient 119
from HER2-Enriched to Luminal A, and patient 123 did not change
and was classified as Luminal B at both time points. Collectively,
these data indicated that intrinsic subtype could not explain these
variations in short-term, drug-induced expression changes.
The three matched pairs of samples that underwent the
strongest molecular response within 7 days did not exhibit
significantly higher HER2 expression and were not exclusively
HER2-Enriched intrinsic subtype at baseline. When the three pre-
treatment samples were compared to all other pre-treatment
samples they had significantly higher expression of PSMD3, a gene
located within the HER2 amplicon at 17q21.1 (Supplementary Fig.
4c and Supplementary Data 6). These pre-treatment samples also
had higher HER2-amplicon gene expression module score when
compared to the less responsive samples (Supplementary Fig. 4d
and Supplementary Data 7). This observation supports other
findings that increased HER2 amplification or HER2 amplicon score
may identify those tumors that are more HER2-addicted and more
likely to exhibit a high degree of dynamic response9.
As our preclinical analysis had implicated FOXA1 in the adaptive
response to HER2 inhibition, we assessed FOXA1 expression
levels in matched patient samples (Fig. 4c). The three strongly
responsive samples identified by unsupervised approaches had
the largest decreases in FOXA1 in response to treatment. To
identify genes behaving in a manner similar to FOXA1, we
performed unsupervised hierarchical clustering of the log2 fold
change of the top 5000 differentially expressed genes. Nearest
neighbor analysis for the FOXA1 gene response was performed to
rank genes by Pearson correlation (Fig. 4d). The change in FOXA1
strongly coincided with a number of epithelial marker genes
(GRHL2, CDH1, and EPCAM) as well as HER3. Additionally,
expression of HER2, DDR1, and the TFs GATA3, XBP1, and PBX1
were also strongly correlated with FOXA1. To validate this
observed correlation, we analyzed the genes correlated with
FOXA1 using TCGA provisional RNAseq data from the Breast
Invasive Carcinoma samples using cbioportal.org41,42. The highest
correlation with FOXA1 was ESR1 (ER), consistent with a critical role
for FOXA1 as a pioneer factor for ER. However, when we used
HER3, the most strongly correlated genes were FOXA1 and XBP1,
by Spearman correlation (Fig. 4e and data not shown).
Given the response of FOXA1 in the three distinct matched
sample pairs, we performed expression pathway analysis and
marker selection to identify the most significantly altered pathway
scores (as log2 fold change) in response to treatment (Fig. 4f). In
addition to increases in a number of immune signatures, we
observed decreases in HER2, HER2 amplicon, MYC, PI3K, KRAS, and
E2F1 modules (10% FDR). These data revealed a distinct subset of
patient sample pairs were characterized by rapid and dramatically
reduced FOXA1 expression coincident with HER3 and HER2
expression changes, as well as immune signature increases
consistent with the trastuzumab and pertuzumab inducing an
immune cell infiltration in these patient tumors and proliferative
signature decreases. These strongly responsive samples showed
higher HER2 amplicon pathway activity at baseline (pre-
treatment).
Distinctly responsive patient samples share discrete TF and
functional kinome features
Given the connection between FOXA1, HER2, and HER3 and
strong molecular responses in the matched patient samples, we
included unmatched clinical trial specimens for further analysis.
Initially, principal component analysis (PCA) of the expressed
kinome from RNAseq analysis was performed (Fig. 5a). The three
distinctly responsive samples (116, 119, and 123) were nearest to
three other samples (109, 118, and 121) when their post-treatment
kinome expression data was used. Unsupervised hierarchical
clustering of all evaluable samples revealed a segregated cluster
of the same 6 post-treatment samples (Supplementary Fig. 5a).
This response was not exclusive to the kinome, as unsupervised
hierarchical clustering based upon the top 2000 differentially
expressed genes led to similar segregation (Supplementary Fig.
5b). Importantly, these six post-treatment samples were from two
different medical centers, suggesting that the differences were not
attributable to technical differences introduced by tissue handling.
The distinct group of six post-treatment samples also included a
patient specimen from each of the four treatment arms, implying
that the transcriptional response was not dependent on a specific
HER2 treatment regimen.
Pathway analysis of the distinct post-treatment samples using
Enrichr identified a significant enrichment for increased immune
response and decreased HER2/HER3 pathway activity associated
with the kinase PTK6 and TF FOXA1 (Supplementary Fig. 5c and
Supplementary Data 8). Together, the changes in gene expression
activity confirmed that this discrete subset of post-treatment
patient tumors were dynamically responsive after 7 days of HER2
antibody treatment with evidence of immune infiltration and
activation.
To analyze the kinome response, we performed differential
expression analysis by DESeq2, comparing the strongly responsive
and weakly responsive subsets of post-treatment tumor samples
(Fig. 5b and Supplementary Data 9). Kinases with significantly
increased expression in the responsive cluster included numerous
immune-associated and mesenchymal genes such as TGFBR2,
CSF1R, LCK, and PIK3CD, consistent with the observed increase in
immune gene expression signatures. Kinases with notable
changes in significance and magnitude included HER2, HER3,
and PTK6 (also known as Brk, breast tumor kinase).
Fig. 4 Distinctly responsive patient samples are marked by dramatic FOXA1 loss, HER3 and HER2 decreases and increased immune
signatures. a Schematic overview of LCCC1214 (Clinical trials identifier NCT01875666) for the analysis of adaptive responses to HER2 targeted
therapy. b Normalized RNAseq data from matched patient samples was used to generate log2 fold changes for expressed genes (post-
treatment vs. pre-treatment). The fold change in expression was used for the principal component analysis (PCA). Labels indicate patient
number and dot color indicates treatment arm. The blue dashed line indicates distinct matched samples (from patients 116, 119, and 123)
determined to be strongly responsive based on their distinct expression changes. c Log2 fold change for FOXA1 for matched patient samples is
plotted. The blue dashed line indicates the strongly responsive sample pairs. d Log2 fold changes of the top 5000 differentially expressed
genes for matched patient samples were used for unsupervised hierarchical clustering and nearest neighbor analysis was performed for the
FOXA1. The top 10 genes by Pearson correlation are indicated, as well as select genes identified from HER2+ cell line SE analysis. e The breast
invasive carcinoma (TCGA, provisional) data set was used to identify genes most significantly co-expressed with HER3 expression in patient
tumors. The top genes were XBP1 (not shown) and FOXA1. The dashed line indicates regression line. Table contains legend for mutation status,
if known. f Pathway analysis of gene expression data from matched patient samples was performed and the pathway scores differences was
used for marker selection comparing the strongly responsive sample pairs (blue dashed line) to all other sample pairs. The top 25 pathways
(increased and decreased) are shown (10% FDR cutoff ). Representative significant pathways are listed with associated reference.
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We accessed the normalized gene expression data set from a
published clinical trial, 03-311 (NCT00148668)39. The 03-311 data
set included 50 matched pre- and post-treatment sample pairs
where HER2+ patients received a single dose of trastuzumab and
underwent surgery 7–14 days later. To compare our findings in
exclusively post-treatment samples, we initially filtered the data to
include only the 50 post-treatment tumor samples and analyzed
the expressed kinome (Supplementary Fig. 5d). Unsupervised
hierarchical clustering of the kinome expression data from this
study identified a subgroup of 7 out of 50 total tumor specimens
with a similar profile to the 6 tumors identified in our study.
Marker selection analysis on the distinct cluster of 7 tumors versus
the remaining 43 was performed and an equivalent comparison
was made for our study to highlight any observed similarities
(Fig. 5c). Of the top 20 discriminatory kinases with decreased
expression, 6 were common to both data sets—HER2, HER3, PTK6,
DDR1, TRIB3, and FRK (Fig. 5b, red). As the 03-311 expression
analysis utilized Illumina beadchip arrays, multiple gene probes
were sometimes present. Notably, all probes for HER3 and PTK6
were included among the top discriminatory markers for 03-311.
a b




































































1 2 3 4 5-1-2-3-4-6 -5
log 2 fold change

















































log 2 fold change




































RNAseq - matched patient samples
post-treatment/pre-treatment
f
g MIB/MS: Post/pre kinome response




























































































































































































































































































S.P. Angus et al.
9
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2021)    51 
We also performed clustering of the log2 fold change (post/pre)
for the expressed kinases in the 03-311 study. The same 7 patient
pairs were close in distance and the response of HER2 was strongly
correlated to HER3 and PTK6 (data not shown). Thus, our study and
the 03-311 trial both contained a discrete subset of post-
treatment patient specimens with markedly stronger transcrip-
tional responses of HER2, HER3, PTK6, and other kinases after
1–2 weeks of HER2 antibody therapy.
We next examined the differentially expressed TFs in the select
post-treatment specimens to gain insight into the adaptive
response (Fig. 5d). Numerous immune-associated and mesench-
ymal factors such as AKNA, IRF8, IRF4, and ZEB2 were significantly
increased, consistent with both our global and gene-centric
pathway analyses. We compared the expression of TFs in post-
treatment samples in our study to the 03-311 trastuzumab study
(Fig. 5e). The top 20 discriminatory TFs from the distinctly
responsive post-treatment samples in each study revealed five
common genes—FOXA1, GATA3, CREB3L4, SPDEF, and ESRRG
(Fig. 5d, red). The ETS family member, SPDEF, exhibits high
expression in prostate epithelium and has been shown to
promote luminal breast cancer gene expression and prolifera-
tion43,44. Matched post/pre sample pairs confirmed that the
expression of HER2, HER3, and PTK6 was reduced (Fig. 5f).
The adaptive kinome response was further interrogated using a
chemical proteomic method, MIB/MS, using samples with
sufficient tissue for mass spectrometry analysis. Label-free
quantification (LFQ) of MIB binding was performed using
MaxQuant (MaxLFQ) and the log2 fold change for matched post-
treatment and pre-treatment pairs was determined (Fig. 5g,
Supplementary Fig. 5e, and Supplementary Data 10). Consistent
with our observation from gene expression data, a stacked bar
plot of the top 20 changes in response to treatment in all samples
was enriched for kinases associated with immune cells (e.g., SYK,
FGR, FER, BTK). Thus, the kinome of all samples showed evidence
of treatment using a standard–of-care HER2 antibody.
To focus on the strongly transcriptionally responsive sample
pairs, a stacked bar plot of the 25 kinases with the largest sum
differences in MIB binding (decreased and increased) revealed
that they were characterized by decreased binding of DDR1,
consistent with the RNAseq data, and CDK1, the G2/M cyclin-
dependent kinase associated with proliferation. Kinases with
highest sum increased binding included the mesenchymal marker
PDGFRB and immune-associated kinases FYN and LCK in select
patients. A scatter plot of log2 fold change in MIB binding (x-axis)
and gene expression (y-axis) from two strongly responsive
matched patient samples (116, and 119, Figs. 5h and i) and a
comparatively weakly responsive matched patient sample (120,
Fig. 5j) highlights the consistent increases in immune-associated
kinases such as LCK, CSF1R, and SYK. In contrast, the decreases in
DDR1 and CDK1 expression and MIB binding were more
pronounced in the strongly responsive patient samples. Collec-
tively, analysis of the adaptive kinome response identified an
immune response triggered by HER2-targeted therapy and
confirmed the loss of key proliferative and breast cancer-
associated kinases in the discrete, strongly molecular responsive
subset of patients.
FOXA1-dependent adaptive response gene set applied to
patient sample pairs
To test the assertion that FOXA1 might regulate genes involved in
adaptive response to HER2 inhibition, we used our RNAseq data
from SKBR-3 cells treated with lapatinib or treated with
FOXA1 siRNA (Fig. 3a). Using DESeq2, we identified genes induced
by lapatinib (log2 fold change >1, 5% FDR) and genes whose
expression was reduced by FOXA1 depletion (log2 fold change <1,
5% FDR) and selected the genes present in both sets (Fig. 6a and
Supplementary Data 4). When the 50 intersecting genes were
used to query Enrichr, significant enrichment was observed for
multiple ER and FOXA1 ChIPseq data sets (not shown) which is
consistent with the ER–FOXA1 relationship. We next used the 50
genes (“FOXA1-dependent adaptive response genes”), to generate
a dendogram by unsupervised hierarchical clustering of matched
patient samples (Fig. 6b). Forty-seven of these 50 genes were
expressed and HER3 and the transcription factors TOX3 and XBP1
were among the most strongly downregulated genes from this
set. In SKBR-3 cells, both TOX3 and XBP1 display the strong
induction of proximal SEs following lapatinib treatment that is
blocked by JQ1 treatment (Supplementary Fig. 6 and data not
shown). We also noted the inclusion of VTCN1 (V-set domain
containing T cell activation inhibitor), a gene responsive to NF
kappa B and inflammation and a negative regulator of T cells.
Although this gene set was derived from cell type-specific
expression changes in HER2+/ER− SKBR-3 cells, the strongly
responsive patient samples 116, 119, and 123 could be
discriminated. The 20 genes (upper cluster) displaying a trend
toward strong reduction post-treatment had a significant associa-
tion with HER2 from the “ARCHS4 Kinases Coexpression” set after
Enrichr query (Padj= 0.008050) while the lower cluster (27 genes)
did not. The associated genes included XBP1, SPINK8, BAMBI, and
Fig. 5 Distinctly responsive post-treatment samples share common kinome and transcriptome features following HER2 targeting. a All
post-treatment samples with RNAseq data were used to filter for expressed kinases. The normalized kinome expression data was used for
principal component analysis (PCA). Patient number is indicated in red for each dot and color indicates LCCC1214 treatment arm. Dashed line
indicates previously identified patients 116, 119, and 123 and neighboring samples 109, 118, and 121. b RNAseq expression levels of strongly
responsive post-treatment samples were compared to the less-responsive post-treatment samples by DESeq2 to identify differentially
expressed kinases. The volcano plot indicates the magnitude and the significance of the identified expression differences. Dashed line
indicates FDR 5%. c Log2 normalized gene expression data (GSE76360) of the kinome was analyzed from the 03-311 clinical trial (Clinical trials
identifier NCT00148668), in which patient samples were obtained pre-treatment and after 10–14 days of trastuzumab. Post-treatment gene
expression data of the kinome was used for unsupervised hierarchical clustering and a segregated cluster of 7 post-treatment patient samples
(of 50 total) was identified. Marker selection was performed in Morpheus (Broad Institute) to identify the top 20 kinases significantly down in
the strongly responsive post-treatment samples for 03-311 trial data and from DESeq2 analysis of the LCCC1214 trial from (b). Venn diagram
shows the 6 kinases common to both data sets. Asterisks indicate that more than one gene probe was identified by marker selection for the
03-311 data set (Illumina expression beadchip). d DESeq2 analysis of differentially expressed transcription factors in the strongly responsive
versus weakly responsive post-treatment LCCC1214 samples. The volcano plot indicates the magnitude and the significance of the identified
expression differences. e Marker selection was performed in Morpheus (Broad Institute) to identify the top 20 transcription factors with
decreased expression in the strongly responsive post-treatment samples for 03-311 trial and compared with the DESeq2 analysis for LCCC1214
from (a). The Venn diagram shows the 5 transcription factors common to both clinical data sets. f The post-treatment/pre-treatment log2 fold
change of HER2, HER3, and PTK6 expression is shown for paired patient samples. g Paired post-treatment and pre-treatment samples from the
LCCC1214 study were processed for kinome analysis by MIB/MS. The log2 MIB binding changes (post/pre) were plotted as the sum of strongly
molecular responsive samples (patients 109, 116, 119, and 121) versus the average difference for weakly-responsive matched pairs and the top
25 differences in both directions are shown. h–j Log2 fold changes for the indicated matched patient samples as determined by MIB binding
(x-axis) and RNAseq (y-axis).
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VTCN1. The broad effects on enhancers, gene expression, and
phenotype imply that multiple genes may be involved, possibly a
TF network, but that FOXA1 reduction elicits a significant response
to lapatinib. Taken together, these findings suggest that an ER-
independent role is played by FOXA1 in mediating adaptive
responses to HER2 inhibition.
DISCUSSION
HER2 targeting using a variety of available drugs has transformed
outcome in this subset of breast cancers. However, resistance
remains a problem both in the early and metastatic settings.
Moreover, due to the relatively low responsiveness to HER2-
targeted drugs alone, the treatment regimens usually include
some form of cytotoxic agent. This is the reason that optimizing
the effectiveness of all-biologic regimens and identifying the basis
for exceptional response is so attractive. Our integrative analysis in
HER2+ models implicated FOXA1 as a mediator of gene
expression and lineage, irrespective of ER status. While both
RNAseq expression analysis and proteomic analysis of the kinome
revealed immune responses characteristic of HER2 antibody
treatment, we observed a distinct subset of HER2+ patient
tumors with comparatively stronger molecular responses. These
specimens exhibited dynamic immune pathway alterations and
more dramatic reduction in FOXA1, HER2, HER3 and proliferative
kinases such as CDK1. Dramatically higher responses in HER2,
HER3, and FOXA1 seen in a subset of post-treatment samples was
also seen in a subset of patients from an independent clinical trial.
We observed that higher HER2 amplicon pathway was associated
with early molecular responses. Immune cell activation has been
consistently associated with clinical and molecular response to
HER2-directed therapy; we also found increases in immune
signatures, as well as PD-1 and PD-L1 gene expression 7 days
after initiating treatment (Supplementary Fig. 7).
FOXA1 is predominantly considered a pioneer factor for ER from
studies in ER+ breast cancer as well as the androgen receptor (AR)
in prostate cancer, promoting chromatin accessibility for these
TFs28,34,45. The expression of FOXA1 correlates with ER expression,
with better prognosis, and is amongst the classifier genes in the
PAM50 intrinsic subtype classifier46. The shared cell lineage of
HER2+ breast cancer with other luminal breast cancers prompted
deeper investigation into a potential role for FOXA1 in HER2+/ER
− breast cancer47. FOXA1 was recently identified as an essential
gene in luminal breast cancer cell lines48. Based on our findings,
we propose that FOXA1 is key to HER2+ breast cancer cell identity
and adaptive reprogramming. The notion of transcription factor
addiction may be true for FOXA1 in HER2+/ER− breast cancer.
The recent integration of large data sets to identify dependencies,
depMap (https://depmap.org/portal/), further supports that
FOXA1 is embedded in breast epithelial lineage, with enriched
dependencies for ER+ and HER2+ cell populations. Given that
FOXA1 has been shown to function in response to proinflamma-
tory signaling and endocrine resistance in breast cancer cells and
in regulatory T cells49–51, it will be critical to discriminate FOXA1-
dependent, cell type-specific effects. Recruitment of FOXA1 to
specific regions, such as the HER3 intronic enrichment in response
to lapatinib observed here (Supplementary Fig. 3) merits further
functional studies to establish the requirement of these interac-
tions for HER3 induction.
Recently, Toska et al. demonstrated the cooperative interplay of
FOXA1, PBX1, and the histone methyltransferase KMT2D, in the

























































































Fig. 6 A FOXA1-dependent adaptive response gene set discrimi-
nates strongly responsive patient samples. a DESeq2 analysis of
SKBR-3 cells treated with lapatinib vs. DMSO or with siRNA targeting
FOXA1 vs. non-targeting siRNA was performed to identify genes
upregulated or downregulated, respectively, with log2 fold change
of ≥ 1 or ≤ 1, respectively, and FDR cut-off of 5%. The number of
genes in each list was compared and the overlap is shown in the
Venn diagram to identify FOXA1-dependent genes responsive to
HER2 targeting with lapatinib. b Log2 fold changes in expression for
matched patient samples from the gene set identified in (a) was
used to perform unsupervised hierarchical clustering.
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Epigenetic alterations are a key source of acquired resistance to
HER2-directed therapy and potential targetability53–57. Trials
combining HDAC inhibitors with anti-HER2 drugs have had mixed
results but all are small and tolerability has been an issue,
although a recent study using entinostat demonstrated some
promise58.
Wang et al. recently demonstrated that BET bromodomain
inhibitors, including JQ1, could interfere with FOXA1-dependent
repression and promote prostate cancer invasion59. This is
consistent with the dramatic effects we observed with either
JQ1 treatment or FOXA1 depletion in combination with HER2
targeting (Figs. 1g and 2h). This observation should prompt
deeper investigation into both HER2+ and ER+ breast cancer
models to elucidate the potential impact of BET bromodomain
inhibitors on FOXA1 function. Ongoing and recently completed
Phase I studies of BET inhibitors in multiple solid tumors
(NCI02259114, NCT03220347, and NCT03035591) suggest that
combinations could be employed with HER2-targeting agents. A
recent study from Gao et al. demonstrated that demethylation of
lysine 270 of FOXA1 by LSD1 was critical for FOXA1 function in
prostate cancer models60. A small molecule inhibitor of LSD1
(GSK2879552) was effective alone and in combination with AR-
targeting enzalutamide in prostate cancer xenograft models. It
remains to be determined whether similar effects can be observed
using LSD1 inhibition in breast cancer models.
We are aware that limitations of this study include (1) the size of
the window-of-opportunity trial, making it not feasible to identify
variations in adaptive response mechanisms by drug combination
(antibody alone or antibody plus small molecule, for example),
and (2) by virtue of the short duration of drug exposure in this
trial, it is not possible to associate adaptive changes with clinical
endpoints. Nonetheless, this study builds upon existing and
emerging evidence of the nature and importance of short-term
adaptive responses to kinase inhibition. Our prior work in both
triple-negative and HER2+ breast cancer suggest heterogeneity in
adaptive reprogramming makes targeting the response challen-
ging; in this study we have found in HER2+ breast tumors that
targeting underlying epigenetic mechanisms of reprogramming
may be feasible and circumvent variability in expressed adapta-
tions. Like other investigators, we found that immune cell
response to anti-HER2-therapy occurs very early; we also found
that this short-term response was similar across several anti-HER2
drugs. The other major early and prominent adaptive response is
related to FOXA1 and our findings suggest a role for this master TF
in adaptive response to HER2-targeted therapy. Thus, ongoing
efforts to disrupt FOXA1 as a means to augment treatment of ER+
breast cancer may be useful for HER2+/ER− disease as well.
METHODS
LCCC1214/TBCRC 036 window-of-opportunity clinical trial
The LCCC1214/TBCRC 036 window trial, “Defining the HER2 Positive (+)
Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combina-
tion Trastuzumab+ Pertuzumab, or Combination Trastuzumab+ Lapati-
nib” is registered under the ClinicalTrials.gov identifier NCT01875666 (date
of registration, 6/13/2014). GlaxoSmithKline generously provided lapatinib
(Tykerb™) and Genentech, Inc. generously provided trastuzumab (Hercep-
tin™) and pertuzumab (Perjeta™) for the study. Eligible women included
those with newly diagnosed Stage I–IV HER2+ breast cancer scheduled to
undergo definitive surgery (either lumpectomy or mastectomy). Stage I–IIIc
patients could not be candidates for a therapeutic neoadjuvant treatment.
Histological confirmation of HER2+ status was determined by IHC 3+ or by
fluorescence in situ hybridization (FISH), clinical assays on either primary or
metastatic tumor. Study subjects provided informed written consent that
included details of the non-therapeutic nature of the trial, and the study
was approved by the UNC Office of Human Research Ethics and conducted
in accordance with the Declaration of Helsinki. Twenty-two patients were
enrolled at three institutions (UNC, Dana Farber, MD Anderson) between
10/31/2013 and 12/6/2016, of whom 15 were randomized to a treatment
arm (4A, 3B, 4C, 4D). The remaining 7 either declined a required study
procedure after enrollment or were found ineligible (e.g., ineligible based
on pretreatment laboratory values), some of whom had research biopsies
already collected on an institutional tissue banking protocol so could
contribute pre-treatment samples for analysis but could not contribute
post-treatment samples. No patient had a treatment-related adverse event
during the course of study treatment or follow-up. The study was closed
for completion of enrollment for this purely correlative trial. For 13 of these
patients, matched pre-treatment and post-treatment samples were
collected while for 8 additional patients, only a single pre-treatment or
post-treatment sample of sufficient quality was available.
Following enrollment, patients were randomly assigned to one of four
treatment arms; (A) single dose trastuzumab (8 mg/kg IV); (B) single dose
pertuzumab (840mg); (C) combination trastuzumab (8 mg/kg)+ pertuzu-
mab (840mg) for one dose each; or (D) combination single dose
trastuzumab plus oral lapatinib (1000mg daily) for one week. Study
subjects underwent core biopsy of the breast tumor (pre-treatment),
received treatment for 7 days prior to the scheduled surgery date. At
surgery, a post-treatment tumor specimen was reserved for research.
Biopsy and surgical specimens were immediately placed into liquid
nitrogen. Flash-frozen pre- and post-treatment samples were processed for
RNAseq and for kinome profiling by MIB/MS to evaluate adaptive response
to HER2-targeted therapy.
Next-generation RNA sequencing
RNA was extracted from frozen patient specimens, cell lines, or frozen PDX
tumors using Qiagen RNeasy Plus Kit with optional DNase I treatment.
Libraries were prepared using the KAPA Stranded mRNAseq kit according
to the manufacturer’s protocol with 12 cycles of PCR amplification.
Samples were indexed with Illumina TruSeq adaptors. Samples were run
on an Illumina NextSeq 500 using High Output Kits to produce single end
75 bp or paired-end 50 bp reads.
RNAseq analysis and PAM50 intrinsic subtyping
FastQC-passed reads were aligned to the human reference genome (hg38)
using STAR 2.4.2a61 and reads were translated to transcriptome
coordinates using Salmon 0.6062. Isoform data were collated to single
gene IDs using the R package biomaRt63, and abundance estimates
were upper quartile normalized using R. Gene values were filtered to
include only those with 10 or more reads in at least one sample and values
(x+ 1) were log2 transformed and used for unsupervised hierarchical
clustering (complete linkage) in Morpheus (https://software.broadinstitute.
org/morpheus/). DESeq2 was used for differential expression analysis using
raw counts and an FDR cut-off of 5% was used to filter genes used for
Enrichr analysis64,65. LCCC1214 samples went through standard PAM50
algorithm, samples were classified into 5 different breast cancer subtypes
based on the 50 intrinsic gene scores and classification66.
RNAseq pathway signature analysis
In order to implement each signature, the methods detailed in the original
studies were followed as closely as possible67. The gene expression data
set was log2 transformed, median centered, and filtered to exclude genes
with missing value in more than 20% of the samples. The mean expression
value was then calculated using all genes within a given signature and the
resulting signature scores are reported in the Supplementary Data 5.
Statistical analysis was performed using SAM (q < 0.05) to identify
significant differences in pathway activity between strong and weak
responsive post-treatment samples as well as pre-treatment samples for
the matched pairs. Unsupervised hierarchical clustering of pathway
signatures (complete linkage) was performed using Gene Cluster 3.0 and
Java Treeview was used to visualize the resultant heat maps.
MIB chromatography, LC-MS/MS, and analysis
Flash-frozen tumor samples were crushed by mortar and pestle in ice-cold
MIB lysis buffer and MIB chromatography performed as previously
described. Extracts were sonicated 3 × 10 s, clarified by centrifugation,
and syringe-filtered (0.22 μm) prior to Bradford assay quantitation of
concentration. Equal amounts of total protein (0.3 mg) were gravity-flowed
over multiplexed inhibitor bead (MIB) columns in high salt MIB lysis (1 M
NaCl). The MIB columns consisted of 175 μl mixture of six Type I kinase
inhibitors (CTx0294885, VI-16832, PP58, Purvalanol B, UNC-21474, and
UNC-8088A) custom-synthesized with hydrocarbon linkers and covalently
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linked to ECH-Sepharose (or EAH-Sepharose for Purvalanol B) beads as
previously described12,19. Columns were washed with 5mL of high salt
(1 M NaCl), 5 mL of low salt (150mM NaCl) MIB lysis buffer, and 0.5 mL low-
salt lysis buffer with 0.1%SDS. Bound protein was eluted twice with 0.5%
SDS, 1% beta-mercaptoethanol, 100 mM Tris-HCl, pH 6.8 for 15min at
100 °C. Eluate was treated with DTT (5 mM) for 25min at 60 °C and 20mM
iodoacetamide for 30min in the dark. Following spin concentration using
Amicon Ultra-4 (10k cut-off) to ~100 μL, samples were precipitated by
methanol/chloroform, dried in a speedvac and resuspended in 50mM
HEPES (pH 8.0). Tryptic digests were performed overnight at 37 °C,
extracted four times with 1 mL ethyl acetate to remove detergent, dried in
a speed-vac, and peptides further cleaned using C-18 spin columns
according to the manufacturer’s protocol (Pierce). Peptides were
resuspended in 2% ACN and 0.1% formic acid. 40% of the final peptide
suspension was injected onto a Thermo Easy-Spray 75 μm× 25 cm C-18
column and separated on a 120min gradient (5–40% ACN) using an Easy
nLC-1200. The Thermo Q Exactive HF mass spectrometry ESI parameters
were as follows: 3e6 AGC MS1, 80ms MS1 max inject time, 1e5 AGC MS2,
100ms MS2 max inject time, 20 loop count, 1.8m/z isolation window, 45 s
dynamic exclusion. Raw files were processed for label-free quantification
by MaxQuant LFQ using the Uniprot/Swiss-Prot human database and
default parameters were used with the following exceptions—only unique
peptides were used, carbidomethyl (C) fixed modification, and phospho
(STY) dynamic modifications, and matching between runs was utilized. In
Perseus software (Max Planck Institute), LFQ intensities were log2-
transformed and missing values were imputed by column using default
parameters.
Cell lines, authentication, and in vitro treatment
SKBR-3 and BT474.m1 HER2+ breast cancer lines were grown in RPMI
1640 supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin. These lines obtained from UNC Lineberger Tissue Culture
Facility or collaborators, cultured no more than 6 months, and routinely
checked for mycoplasma contamination by DAPI staining. Cells were
treated for 24 h with lapatinib (300 nmol/L final concentration) or JQ1
(300 nmol/L final concentration) purchased from Selleck Chemicals and
dissolved in DMSO.
Chromatin immunoprecipitation, library preparation, and
analysis
Chromatin immunoprecipitation (ChIP) experiments were as described
previously20. Briefly, 1 × 107 cells per IP were crosslinked for 10min at room
temperature in 1% formaldehyde and neutralized with a final concentra-
tion of 125mM glycine. Nuclear extracts were sonicated 15 cycles (30 s
pulse, 30 s cooling) using a Bioruptor Pico (Diagenode). Samples were
tumbled overnight at 4 °C with 10 μg antibody (control rabbit IgG
(ThermoFisher, Cat. 02-6102), anti-BRD4 (Bethyl Laboratories, Cat. A301-
985A100), anti-MED1 (Bethyl Laboratories, Cat. A300-793A100), anti-
H3K27ac (Active Motif, Cat. 39133), or anti-FOXA1 (Abcam, Cat. ab5089)
conjugated to protein A Dynabeads (ThermoFisher, Cat. 10006D)). After
washing and RNaseA/proteinase K treatment, DNA was purified using a
Qiagen MinElute PCR purification kit. ChIPseq libraries were prepared using
the KAPA HyperPrep Kit according to the manufacturer’s protocol using an
equal amount of input DNA. Samples were indexed with Illumina TruSeq
adaptors and dual size selection was performed following 16–18 cycles of
PCR amplification. Samples were run as equimolar 12-plexes on an Illumina
NextSeq 500 using a 75 cycle, high output kit to produce single-end 75 bp
reads. Analysis was performed essentially as described by Zawistowski
et al., except that peaks within 20 kb were stitched and peaks defined by
the following criteria: ±5 kb of any transcription start site (TSS)= promoter,
−5 to −200 kb of any TSS= 5′ enhancer, if overlapped with gene
boundary= genebody_exon or genebody_intron, within 0 to +200 kb
from the 3′ most exon and not classified as any other= 3′ enhancer. All
other peaks were defined as “other” or “orphan.” Genes defined as
“proximal” for comparison to expression data were defined as those genes
whose TSS was within 200 kb 5′ of the 5′ edge or 200 kb 3′ of the 3′ edge
of an induced ChIPseq peak.
siRNA transfection, cell proliferation, and western blotting
Dharmacon (now Horizon Discovery) siGENOME SMARTPool siRNAs
targeting MYC (Catalog ID:M-003282-07-0005), FOXA1 (Catalog ID:M-
010319-01-0005), FOXO3 (Catalog ID:M-003007-02-0005), FOXO1 (Catalog
ID:M-003006-03-0005), or Non-Targeting Control Pool #2 (Catalog
ID:D-001206-14-05) were reverse transfected at a final concentration of
25 nM with RNAiMAX (Life Technologies). siRNAs were mixed with 1/1000
final volume RNAiMAX in serum- and antibiotic-free IMDM and incubated
at room temperature for 20–30min before plating trypsinized cells in RPMI
1640 media with 10% FBS and antibiotics. For drug treatment, cells were
incubated in siRNA for 24 h before replacement of media with DMSO or
drug-containing media. Cells were plated (SKBR-3: 4,000 cells/well and
BT474.m1: 6000 cells/well) in 96-well plates and drug-containing media
was replenished every 24 h. Live cells were stained with Hoechst in PBS for
20min at 37 degrees C and imaged/counted with a Thermo Cellomics
ArrayScan VTI at 25 frames per well. Equal amounts of extracted protein
(determined by Bradford assay) were separated by SDS-PAGE, transferred
to nitrocellulose and probed with anti-BRD4 (Bethyl Laboratories, Cat.
A301-985A100, 1:1000), anti-ERK2 (Santa Cruz Cat. sc-1647, 1:2000), anti-
FOXA1 (Abcam, Cat. ab5089, 1:1000) or the following antibodies (all with
Cell Signaling Cat. numbers and used at 1:1000): anti-FOXO1 (2880), anti-
FOXO3 (2497), anti-phospho-HER2/ErbB2 (Tyr1221/1222) (2243), anti-HER2
(2242), anti-HER3 (4754), anti-phospho-AKT (Thr308) (4056), anti-phospho-
AKT (Ser473) (4060), anti-phospho-ERK1/2 (4370). All western blots shown
derive from the same experiment, were processed in parallel, and are
representative of at least two experiments. Uncropped images are
included in the Supplementary Material.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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